symbol CRY
会社名 CryoLife Inc. (CRYOLIFE)
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 クライオライフ(CryoLife Inc.)は医療機器の製造者とプロセッサーであり、医療機器および心臓外科手術に応用する移植可能なヒト組織の流通を行う。同社は医療機器および保存サービス、二つのセグメントで事業を展開する。医療機器セグメントはBioGlue Surgical Adhesive、BioFoam Surgical Matrixなどの医療機器、弁と外科用製品、CardioGenesis心臓レーザー治療製品ライン、PerClotとPhotoFixを含む。PhotoFixはグルタルアルデヒドの必要ない色素媒介光固定プロセスを用いて安定化された心膜パッチである。保存サービスセグメントは心臓および血管組織の保存などの外部サービスを含む。CryoLife iによって配布される心臓および血管組織はCryoLifeのSynerGraft技術を利用して処理されたCryoValve SG肺心臓弁およびCryoPatch SG肺心臓パッチを含む。  クライオライフは米国の医療用機器関連製造会社。心臓と血管アプリケ―ションのための医療用デバイスの開発、製造、商品化。また、移植用のヒト組織の保管と流通を行う。冠動脈疾患患者にレ―ザ―コンソ―ルシステム、狭心症患者に使い捨ての光ファイバ―ハンドピ―スを使用して治療。その他、末期腎疾患患者用の血液透析機器の販売。  CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. It operates through the following segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of BioGlue; JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PerClot and PhotoFix. The Preservation Services segment focuses on external services revenues from the preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.
本社所在地 1655 Roberts Boulevard N.W. Kennesaw GA 30144 USA
代表者氏名 James Patrick Mackin
代表者役職名 Chairman of the Board President Chief Executive Officer
電話番号 +1 770-419-3355
設立年月日 30682
市場名 NYSE(ニューヨーク証券取引所)
従業員数 1100人
EBITDA (百万ドル) 27.40700
時価総額 (百万ドル) 1103.43100
売上高 (百万ドル) 262.84100
企業価値(EV) (百万ドル) 1285.48900
当期純利益 (百万ドル) -3.05100
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Cryolife Inc revenues increased 39% to $262.8M. Net loss applicable to common stockholders excluding extraordinary items totaled $3.1M vs. income of $3.4M. Revenues reflect Medical Devices segment increase of 57% to $187.4M Preservation services segment increase of 8% to $75.4M International segment increase from $54.6M to $118.2M United States segment increase of 7% to $144.7M.



   CryoLife to Participate in Upcoming Virtual Investor Conferences  2020/08/06 12:35:00 PR Newswire
ATLANTA, Aug. 6, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming virtual investor conferences. CryoLife's management team will present at the upcoming…
   CryoLife Reports Second Quarter 2020 Financial Results  2020/07/30 20:05:00 PR Newswire
ATLANTA, July 30, 2020 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $53.8 million in the second quarter 2020 versus $71.1 million in the second quarter of 2019 - Total revenues decreased 24% and decreased 23% on a non-GAAP constant currency…
   CryoLife Announces Release Date and Teleconference Call Details for 2020 Second Quarter Financial Results  2020/07/21 21:00:00 PR Newswire
ATLANTA, July 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 second quarter financial results will be released on Thursday, July 30, 2020 after the market closes. On that day, the…
   CryoLife Announces Pricing of $100 Million Convertible Senior Notes Offering  2020/06/19 11:05:00 PR Newswire
ATLANTA, June 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of $100 million aggregate principal amount of 4.250% convertible senior notes due 2025…
   CryoLife Announces Offering of Convertible Senior Notes Due 2025  2020/06/18 11:05:00 Benzinga Feeds
ATLANTA , June 18, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY ) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it intends to offer, subject to market conditions and other factors, $100,000,000 aggregate principal amount of convertible senior notes due 2025 (the "Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). CryoLife also intends to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $15,000,000 aggregate principal amount of the Notes. The Notes will be senior unsecured obligations of the Company. The Notes are expected to pay interest semiannually and will mature on July 1, 2025 , unless earlier converted, redeemed or repurchased in accordance with their terms. Conversion of the Notes will be settled in cash, shares …

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 CRYOLIFE CRY )


 twitter  (公式ツイッターやCEOツイッターなど)